Pharmacotherapy and psychotherapy in cannabis withdrawal and dependence

@article{Benyamina2008PharmacotherapyAP,
  title={Pharmacotherapy and psychotherapy in cannabis withdrawal and dependence},
  author={Amine Benyamina and Marie Lecacheux and Lisa Blecha and Michel Reynaud and Michael Lukasiewcz},
  journal={Expert Review of Neurotherapeutics},
  year={2008},
  volume={8},
  pages={479 - 491}
}
Cannabis has long been perceived as a drug causing questionable dependence. Only recently has a clinically recognized withdrawal syndrome been described, thus laying the foundations for specific treatment evaluations. Six different pharmacotherapies have been studied in cannabis withdrawal. Of these, only oral tetrahydrocannabinol, and perhaps mirtazapine, have shown some promise in the specific treatment of withdrawal symptoms. In cannabis dependence, rimonabant, and perhaps buspiron, have… 
Pharmacotherapy for Cannabis Dependence
TLDR
Results from controlled laboratory studies and small open-label clinical studies indicate that buspirone, dronabinol, fluoxetine, lithium and lofexidine may have therapeutic benefit for those seeking treatment for cannabis-related problems.
Pharmacological treatment of cannabis dependence.
TLDR
Results from controlled human laboratory studies and small open-label clinical trials suggest that dronabinol, the COMT inhibitor entacapone, and lithium may warrant further study and controlled clinical trials are needed to evaluate the clinical efficacy of these medications.
[Pharmacological and psychosocial interventions for cannabis use disorders].
TLDR
Clinical research has identified effective psychosocial treatments, but has yet to yield effective pharmacotherapies; advances in understanding of the neurobiology of the cannabinoid system provide optimism that the synthesis of compounds that alter CB(1) receptor site functioning may produce promising medications.
Pharmacotherapies for cannabis dependence.
TLDR
There was some evidence that treatment with preparations containing THC was associated with reduced cannabis withdrawal symptoms and craving, but this latter outcome could not be quantified and the utility of most of the medications to promote cannabis abstinence at the end of treatment was insufficient.
Pharmacotherapies for cannabis dependence.
TLDR
There was no difference in the likelihood of withdrawal from treatment due to adverse effects with THC preparations, SSRIs antidepressants, mixed action antidepressants, anticonvulsants and mood stabilisers, buspirone and N-acetylcysteine compared to placebo (low- to very low-quality evidence), and abstinence at end of treatment was no more likely than with placebo.
Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial.
TLDR
In a treatment-seeking cohort, nabiximols attenuated cannabis withdrawal symptoms and improved patient retention in treatment, however, placebo was as effective as nabximols in promoting long-term reductions in cannabis use following medication cessation.
Progress toward pharmacotherapies for cannabis-use disorder: an evidence-based review
TLDR
Evidence has shown a decrease in the age of commencement of cannabis use in some developed countries and a prolongation of risk of initiation to cannabis use beyond adolescence among more recent users.
Cannabis Withdrawal: a Review of Neurobiological Mechanisms and Sex Differences
TLDR
Pre-clinical and clinical research on the etiology and biological substrates of the cannabis withdrawal syndrome are provided, and females have been shown to have increased rate and severity of a subset of cannabis withdrawal symptoms compared with men.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 61 REFERENCES
Brief treatments for cannabis dependence: findings from a randomized multisite trial.
TLDR
The 9-session treatment reduced marijuana smoking and associated consequences significantly more than the 2- session treatment, which also reduced marijuana use relative to the DTC condition.
Clinical trial of abstinence-based vouchers and cognitive-behavioral therapy for cannabis dependence.
TLDR
It is suggested that a program of abstinence-based vouchers is a potent treatment option for extended periods of continuous marijuana abstinence during treatment, and cognitive-behavioral therapy enhanced the posttreatment maintenance of the initial positive effect of vouchers on abstinence.
The cost-effectiveness of four treatments for marijuana dependence.
TLDR
The results are shown to be robust to sensitivity analyses on several key cost parameters and patient outcomes measured during the 6-month follow-up period, and its cost-effectiveness over a comparatively wide range of threshold values underscores the promise of this approach.
Pharmacotherapy for marijuana dependence: a double-blind, placebo-controlled pilot study of divalproex sodium.
TLDR
It is found that marijuana-dependent patients will seek treatment, and such patients can be adequately maintained in a pharmacologic trial, and divalproex sodium showed promise as a treatment agent for marijuana dependence.
Treatment of marijuana dependence: a review of the literature.
Bupropion SR worsens mood during marijuana withdrawal in humans
TLDR
Bupropion does not show promise as a potential treatment medication for marijuana dependence, and ratings of irritability, restlessness, depression, and trouble sleeping were increased by bupropion compared to placebo maintenance.
Clozapine use and relapses of substance use disorder among patients with co-occurring schizophrenia and substance use disorders.
TLDR
Clozapine should be considered for the treatment of patients with schizophrenia and co-occurring substance use disorder to prevent relapses to substance abuse, and is associated with prevention of substance abuse relapses.
...
1
2
3
4
5
...